Maze Therapeutics Balance Sheet
NASDAQ: MAZEHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Maze Therapeutics financial position
At the end of fiscal 2025, Maze Therapeutics reported total assets of $397.1 million, up 65.1% from a year earlier against total liabilities of $42.2 million. Shareholders' equity stood at $355.0 million, or 89.4% of assets. The company held $189.2 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 15.50, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Maze Therapeutics balance sheet (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 |
|---|---|---|
| Cash & Equivalents | 189.25M | 196.81M |
| Short-Term Investments | 152.67M | — |
| Total Current Assets | 349.72M | 201.67M |
| Property, Plant & Equipment | 5.04M | 6.67M |
| Long-Term Investments | 18.11M | — |
| Total Assets | 397.13M | 240.54M |
| Accounts Payable | 1.79M | 1.94M |
| Total Current Liabilities | 22.56M | 20.67M |
| Total Liabilities | 42.16M | 43.64M |
| Shareholders' Equity | 354.97M | -311.18M |
| Retained Earnings | -489.55M | -358.43M |
| Net Cash (Debt) | 341.92M | 196.81M |
| Shares Outstanding | 49.34M | 2.45M |
This table shows 2 annual periods of Maze Therapeutics's balance sheet, from FY 2025 back to FY 2024, across 13 line items including cash & equivalents, short-term investments, total current assets. Values in USD; B = billions, M = millions. Fiscal periods follow MAZE's reporting calendar. What is a balance sheet?